CEL-SCI
Blood & Organ Banks · Virginia, United States · Employees
View Company Info for Free
Overview
Headquarters
8229 Boone Blvd Ste 802, Vienna, Virgini...Phone Number
(703) 506-9460Website
www.cel-sci.comRevenue
-Stock Symbol
CVMIndustry
About CEL-SCI
CEL-SCI Corporation is a biotechnology company focused on developing immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. Their flagship products, Multikine and LEAPS, aim to harness the immune system to improve patient outcomes, particularly in cancer treatment. The company is dedicated to innovative research and has conducted the largest Phase III clinical trial in head and neck cancer, demonstrating significant survival benefits. CEL-SCI's mission is to change the way cancer is treated by boosting patients' immune systems before conventional therapies.Explore more
CEL-SCI Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to CEL-SCI
Compare insights from companies similar to CEL-SCI, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
CEL-SCI Tech Stack
A closer look at the technologies used by CEL-SCI
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CEL-SCI
Sign Up For FreeTo access detailed company insights
CEL-SCI Corporation is a biotechnology company focused on developing immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. Their flagship products, Multikine and LEAPS, aim to harness the immune system to improve patient outcomes, particularly in cancer treatment. The company is dedicated to innovative research an... Read More
